Additional Content Download

Finance Transformation in the Pharmaceutical Industry

Finance Transformation in the Pharmaceutical Industry

This whitepaper, courtesy of RSM, tackles the increasingly complex pharmaceutical business model from the R&D and pre-clinical phase, through FDA approval and commercialization.

The Economic Footprint of the Pharmaceutical Industry – Regional Breakdown and Differentiation between Originators and Generics

The Economic Footprint of the Pharmaceutical Industry – Regional Breakdown and Differentiation between Originators and Generics

This study independently conducted by WifOR reveals how the pharmaceutical industry, one of the world’s largest industries, plays a major role in boosting the global economy across regions. This study was commissioned by the IFPMA and aims to refine the study on ‘Measuring the economic footprint of the pharmaceutical industry – Feasibility study’ that examined for the first time the global economic importance of the pharma industry.

Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts

Social Security Finance Bill 2016 in France: French Government Looks To Make 50% Of Healthcare Savings Through Drug Price Cuts

With there being a 12.8 million Euro deficit in France’s 2015 budget, the French government announced on 24th September plans for the Projet de Loi de Financement de la Sécurité Sociale 2016 (PLFSS; Social Security Finance Bill 2016). For the second consecutive year, the PFLSS cost-containment measures include a heavy focus on drug expenditure as part of the...

Gross to Net Principles

Gross to Net Principles

This presentation, courtesy of Deloitte, goes into types of pricing adjustments, the G2N estimation process, updates on hot G2N topics, sales returns, and more!

Pharma & Biotech’s Merger Fever: The Highlights

Pharma & Biotech’s Merger Fever: The Highlights

In 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with the total value of pharma M&As in the first two quarters of 2015 sitting at $221 billion. Read more!
Chargeback 101

Chargeback 101

In this presentation, learn the steps to understanding chargeback and how it impacts your bottom line. Topics include understanding the relationship between chargeback for commercial vs. government pricing and contracting departments, overcoming disputes and deductions by your wholesaler partners, and more.
Leverage Customer Data to Make Improved Accrual Decisions

Leverage Customer Data to Make Improved Accrual Decisions

In this presentation, learn how to enable interdepartmental collaboration to ensure all relevant customer data is efficiently and accurately collected, and how to develop strategic forecasts that are capable of driving aggressive business growth.
GTN Forecasting, Accruals and Analytics

GTN Forecasting, Accruals and Analytics

In this presentation, learn more about some of the key challenges in GTN and how to successfully solve them to mitigate risk and drive good business decisions.
Commercial Analytics & How They Can Impact the Financial Close

Commercial Analytics & How They Can Impact the Financial Close

In this presentation, learn the fundamentals to preparing for the close process, including how using data and discussion can drive contracting, forecasting complexity, and the data requirements for contracting and forecasting results before you start the close process.